PolyMedica boss blasts whispering campaign
This article was originally published in Clinica
Stung by a week in which his company saw its share price plunge from more than $26 to just above $15 and its reputation challenged, PolyMedica's chairman and CEO Steven Lee has responded by saying that the company has been victim of a "barrage of anonymous and unsubstantiated rumours".
You may also be interested in...
Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.
Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.
Following hot on the heels of its Rapidly Manufactured Ventilator Specification document, the UK’s regulator has issued another speedy regulatory permit for fast production of respiratory assist devices.